Literature DB >> 21868558

Effect of glutathione-S-transferase M1 and T1 allelic polymorphisms on HPV-induced cervical precancer formation.

József Cseh1, Emese Pázsit, Zsuzsa Orsós, Erika Marek, András Huszár, Sándor Balogh, István Ember, István Kiss.   

Abstract

AIM: The effect of GSTM1 and GSTT1 allelic polymorphisms was studied on the HPV-induced cervical carcinogenesis. PATIENTS AND METHODS: Two hundred and fifty-three women with persistent high-risk HPV infection were involved in the study; 117 of them developed cervical high-grade dysplasia and/or cervical intraepithelial neoplasia grade III during the 7-year follow-up period. Occurrence of GSTM1 and GSTT1 null genotypes was compared between women with and without dysplasia.
RESULTS: Presence of GSTM1 (OR=1.78, 95% CI=1.06-2.97; p=0.028) and GSTT1 (OR=1.89, 95% CI=1.10-3.26; p=0.022) null genotypes was statistically significantly more frequent among women with cervical dysplasia than in the group without dysplasia. Participants with dual null genotype had an even more elevated risk of precancerous lesion (OR=2.35, 95% CI=1.17-4.73; p=0.017).
CONCLUSION: Our study demonstrated the role of both GSTM1 and T1 null genotypes in the development of high-grade cervical dysplasia in a Caucasian population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21868558

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Relationship between GSTM1 and GSTT1 polymorphisms and HPV infection: a systematic review.

Authors:  Ana Paula Reolon Bortolli; Valquíria Kulig Vieira; Emi Elaine Stefanski; Angela Khetly Lazarotto; Léia Carolina Lucio
Journal:  Mol Biol Rep       Date:  2021-08-13       Impact factor: 2.316

2.  Comprehensive analysis of the glutathione S-transferase Mu (GSTM) gene family in ovarian cancer identifies prognostic and expression significance.

Authors:  Juan Zhang; Yan Li; Juan Zou; Chun-Tian Lai; Tian Zeng; Juan Peng; Wen-da Zou; Bei Cao; Dan Liu; Li-Yu Zhu; Hui Li; Yu-Kun Li
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.